|
|
|
|
New drug regimens help control Waldenstrom macroglobulinemia
Clinical Last Updated: 2010-03-03 16:13:01 -0400 (Reuters Health) By David Douglas NEW YORK (Reuters Health) - Adding bortezomib to rituximab, or using single-agent everolimus therapy, look like promising approaches for patients with relapsed or refractory ...
|
|
|
Everolimus Promising for Relapsed Waldenstrom's Macroglobulinemia
In order to use Medscape, your browser must be set to accept cookies delivered by the Medscape site.To find out how to adjust your browser settings to accept cookies, please click here. Medscape uses cookies to customize the site based on the information...
Abstracts in Hematology and Oncology:
Feb 18 2010 10:06PM
Matching: waldenstrom macroglobulinemia
|
Find similar documents
|
|
|
|
Everolimus Promising for Relapsed Waldenstrom's Macroglobulinemia
In order to use Medscape, your browser must be set to accept cookies delivered by the Medscape site.To find out how to adjust your browser settings to accept cookies, please click here. Medscape uses cookies to customize the site based on the information...
|
|
|
Everolimus Promising for Relapsed Waldenstrom's Macroglobulinemia
_ Everolimus Promising for Relapsed Waldenstrom's Macroglobulinemia.
|
|
|
Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenstrom Macroglobulinemia
Ghobrial IM et al.Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenstrom Macroglobulinemia.
|
|
|
The Leukemia & Lymphoma Society Increases Critical Benefit for Myeloma Patients
WHITE PLAINS, N.Y., Feb.2 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) is pleased to announce that, effective Feb. 1, 2010, patients with myeloma and waldenstrom macroglobulinemia will now be able to receive up to $10,000 in...
|
|
|
Keryx Biopharmaceuticals Announces Positive Phase 2 Study Results of Perifosine as a Single Agent for the Trea
Data Demonstrating a 35% Overall Response Rate with a Median Progression-Free Survival of 12.6 Months in Patients with Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia to be Published in the February 1, 2010 Issue of Clinical Cancer...
|
|
|
Molecular determinants of myeloma bone disease and uses thereof
Title: United States Patent: 7,642,238 Inventors: Shaughnessy; John D.(Little Rock, AR) Appl. No.: 11/176,739 Filed: July 7, 2005 To identify molecular determinants of lytic bone disease in multiple myeloma, the expression profiles of .about.12,000 genes...
|
